Conmed (CNMD) Misses Q4 EPS by 5c, offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CNMD Hot Sheet
Price: $53.66 +13.61%
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Conmed (NYSE: CNMD) reported Q4 EPS of $1.06, $0.05 worse than the analyst estimate of $1.11. Revenue for the quarter came in at $327 million versus the consensus estimate of $332.22 million.
GUIDANCE:
Conmed sees FY2024 EPS of $4.30-$4.40, versus the consensus of $4.40. Conmed sees FY2024 revenue of $1.34-1.365 billion, versus the consensus of $1.357 billion.
For earnings history and earnings-related data on Conmed (CNMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sunrun (RUN) Tops Q3 EPS by 24c
- ITT Inc (ITT) Tops Q3 EPS by 18c ; Offers Guidance
- ADMA Biologics (ADMA) Tops Q3 EPS by 3c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
